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Abstract
The development of effective immunoprophylaxis against tuberculosis (TB) remains a global priority, but is hampered by a
partially protective Bacillus Calmette-Gue´rin (BCG) vaccine and an incomplete understanding of the mechanisms of
immunity to Mycobacterium tuberculosis. Although host genetic factors may be a primary reason for BCG’s variable and
inadequate efficacy, this possibility has not been intensively examined. We hypothesized that Toll-like receptor (TLR)
variation is associated with altered in vivo immune responses to BCG. We examined whether functionally defined TLR
pathway polymorphisms were associated with T cell cytokine responses in whole blood stimulated ex vivo with BCG 10
weeks after newborn BCG vaccination of South African infants. In the primary analysis, polymorphism TLR6_C745T (P249S)
was associated with increased BCG-induced IFN-c in both discovery (n = 240) and validation (n = 240) cohorts. In secondary
analyses of the combined cohort, TLR1_T1805G (I602S) and TLR6_G1083C (synonymous) were associated with increased
IFN-c, TLR6_G1083C and TLR6_C745T were associated with increased IL-2, and TLR1_A1188T was associated with increased
IFN-c and IL-2. For each of these polymorphisms, the hypo-responsive allele, as defined by innate immunity signaling assays,
was associated with increased production of TH1-type T cell cytokines (IFN-c or IL-2). After stimulation with TLR1/6
lipopeptide ligands, PBMCs from TLR1/6-deficient individuals (stratified by TLR1_T1805G and TLR6_C745T hyporesponsive
genotypes) secreted lower amounts of IL-6 and IL-10 compared to those with responsive TLR1/6 genotypes. In contrast, no
IL-12p70 was secreted by PBMCs or monocytes. These data support a mechanism where TLR1/6 polymorphisms modulate
TH1 T-cell polarization through genetic regulation of monocyte IL-10 secretion in the absence of IL-12. These studies
provide evidence that functionally defined innate immune gene variants are associated with the development of adaptive
immune responses after in vivo vaccination against a bacterial pathogen in humans. These findings could potentially guide
novel adjuvant vaccine strategies as well as have implications for IFN-c-based diagnostic testing for TB.
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Introduction
Tuberculosis (TB) is one of the leading causes of mortality
worldwide, with 1.7 million deaths occurring annually [1].
Although murine studies have uncovered numerous genes and
pathways which are critical for effective immune responses to
Mycobacterium tuberculosis (Mtb), the mechanisms of immune
regulation in humans are largely unknown. The current TB
vaccine, Bacillus Calmette-Gue´rin (BCG), is widely used and has
been available since 1921, but provides partial and inconsistent
protection [2,3]. Several hypotheses have been suggested to
explain BCG’s inconsistent efficacy including differences among
BCG vaccine strains, modulation of immune responses by
previous exposure to environmental mycobacteria, and host
genetics [4,5,6]. Evidence presented in numerous studies over the
past 50 years suggests that host genetics influences susceptibility
to TB. First, twin studies indicate that TB rates among
monozygotic twins are more than twice the rate of dizygotic
twins [7]. Second, genome-wide linkage and association studies
(GWAS) have identified several susceptibility loci and efforts to
identify the implicated genes are ongoing [8,9,10,11]. Third,
candidate gene association studies have reported several loci
associated with TB susceptibility and some of these have been
replicated and/or involved polymorphisms with well-character-
ized function [10]. In addition to susceptibility to active TB
disease, host genetic factors may regulate tuberculin skin
reactivity after Mtb exposure or BCG vaccination [12,13,14].
In addition, IFN-c and TNF cytokine responses after ex vivo
stimulation of blood or PBMCs with BCG or Mtb may be
genetically controlled [15,16,17] Although there is wide variation
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in IFN-c levels after BCG vaccination, the genetic mechanisms
which regulate these differences are unknown [18,19]. Under-
standing these differences may illuminate mechanisms of
protective immunity to TB. Furthermore, clinical diagnoses of
TB commonly utilize purified protein derivative PPD skin testing,
which relies on host release of interferon-c (IFN-c) to induce a
positive result. Host factors could confound PPD testing if results
are regulated by genetic variation in IFN-c responses that differ
between individuals. To our knowledge, no studies have
examined whether genetic variants are associated with immuno-
logic or clinical endpoints after BCG vaccination.
Human TLRs are a family of 10 proteins that differentially
recognize pathogen-associated molecular patterns (PAMPs) and
activate signaling cascades that lead to initiation of the innate
immune response and cytokine production, ultimately culminat-
ing in antimicrobial host defenses. Several genes in the TLR
pathway mediate recognition of Mtb including TLRs1, 2, 4, 6,
and 9, which interact with the adaptor proteins MyD88 and
TIRAP/Mal to activate macrophages and dendritic cells [20,21].
In addition to a central role in regulation of innate immunity,
murine studies have shown that TLRs modulate the development
of T cell responses through effects on dendritic cells and antigen
presentation [22,23,24]. Vaccination studies demonstrate that
distinct T cell responses are stimulated when the TLR-ligand
adjuvant is varied. For example, vaccination of mice with
ovalbumin with a TLR4 ligand generates a Th-1 ova-specific
response, whereas ovalbumin with TLR1/2/6 ligands generates a
Th2 response [25]. It is not currently known if TLRs affect
vaccination outcomes in humans and/or whether the type of
modulation is similar to mice.
Human immunology studies have been hampered by population
and experimental heterogeneity, which often limit the level of biologic
insight. We and others have discovered single nucleotide polymor-
phisms (SNPs) and mutations in the TLR pathway that regulate
cellular function and are associated with susceptibility to some
infections, including TB. Hypofunctional polymorphisms have been
reported in TLR1 (T1805G), TLR2 (C597T and G2258A), TLR4
(A896G and C1196T), TLR6 (C745T and G1083C), and TIRAP/
MAL (C539T, G558T) [20,21,26,27,28,29,30,31,32,33,34]. These
TLR-deficient humans offer experimental advantages that are similar
to the characterization of TLR-deficient mice generated with gene
knockout strategies, yet avoid the limitations of mouse models.
Although these polymorphisms regulate NF-kB signaling in transfected
cells and/or are associated with deficient signaling in primary
monocytes, it is not currently known if these or any TLR variants
are associated with in vivo vaccine responses and/or T-cell responses.
We hypothesized that common variants of TLR pathway genes
are associated with in vivo BCG-induced immune responses. To
identify immunogenetic correlates of vaccine responsiveness, we
examined whether functionally defined polymorphisms in TLR
pathway genes are associated with BCG-induced immune
responses 10 weeks after vaccination of infants.
Results
Primary analysis: polymorphism TLR6_C745T is
associated with increased IFN-c production after BCG
vaccination
To investigate whether polymorphisms in innate immunity
genes are associated with vaccine-induced immune responses, we
enrolled South African infants routinely vaccinated with BCG at
birth. Ten weeks after vaccination, we stimulated whole blood ex
vivo with BCG and measured plasma levels of Th1 (IFN-c and IL-
2) and Th2 (IL-13) T cell cytokines. We examined whether 9 well-
characterized SNPs in 5 TLR pathway genes (TLR1, 2, 4, 6, and
TIRAP/MAL) were associated with these cytokine levels. These 9
variants are involved in regulating the immune response to Mtb
and were selected due to their modulation of signaling responses,
and/or association with clinical susceptibility to infection
[21,26,27,28,34,35,36,37,38]. For our primary analysis, we
examined associations in a discovery sample set of 240 and then
validated positive results in a second sample set of 240. One
polymorphism (TLR2_G2258A) was essentially invariant (one
heterozygote detected) and was not analyzed further. Polymor-
phisms TLR6_C745T and TLR6_G1083C were associated with
increased IFN-c and IL-2, respectively, in the discovery sample set
(Table 1 and Figure 1, P= 0.001 and P= 0.024, respectively, for
analysis of BCG-stimulated value after subtraction of unstimulated
control level). To correct for confounding effects from multiple
comparisons, we analyzed the association in a validation set of 240
samples. TLR6_745T was also associated with BCG-increased
IFN-c levels in this sample set (P = 0.03). TLR6_G1083C was not
associated with IL-2 in the validation data set. None of the other
polymorphisms were associated with BCG-induced cytokines in
this primary analysis. TLR6_C745T was not associated with
BCG-induced IL-13 levels or with unstimulated control levels of
any of the cytokines (Figure 1).
We next performed a subgroup analysis to determine whether
the association was affected by population stratification.
TLR6_C745T was associated with increased IFN-c and IL-2
levels in the South African Mixed Ancestry subgroup (Table S1,
P= 0. in combined dataset with n= 371 individuals). We further
examined this subgroup for evidence of population admixture by
examining 21 polymorphisms which were previously selected as
ancestry informative markers in South Africa [39]. We compared
the frequencies of these 21 polymorphisms in groups of low (less
than the median) and high (greater than the median) cytokine
responses. For IFN-c, IL-2, and IL-13, there were no significant
differences in the frequencies of the polymorphisms when
comparing the stratified groups (Table S2, global P values of
0.40, 0.38, and 0.39 for IFN-c, IL-2, and IL-13, respectively).
These data suggested that low and high cytokine responses were
not attributable to population admixture. Together, these results
suggest that TLR6_745T, a hypofunctional polymorphism in
monocyte assays, was associated with increased levels of IFN-c
after BCG vaccination.
Secondary analysis: polymorphisms TLR6_G1083C and
TLR1_T1805G are associated with BCG-induced cytokines
We next performed a secondary analysis of the combined dataset
(n= 480) to increase the power to detect associations of low
frequency polymorphisms with cytokine responses. For low
frequency polymorphisms (minor allele#10%, n=5), we examined
whether variants were associated with BCG-induced cytokines. One
additional polymorphism, TLR1_T1805G was associated with
increased IFN-c production in the combined dataset (Table 2 and
Figure 2). The hypofunctional G allele was associated with higher
Author Summary
Tuberculosis (TB) is one of the leading infectious causes of
death worldwide. The current vaccine for TB, BCG, is widely
used but it is not highly effective in preventing disease. We
investigated the role of host genetics in the immune
response to BCG vaccination. We found that variants of
innate immunity genes (TLR1 and TLR6) were associated
with BCG-induced immune responses after vaccination.
These findings may guide new strategies for vaccine
development as well as diagnosis of TB.
TLR Variation and BCG Response
PLoS Pathogens | www.plospathogens.org 2 August 2011 | Volume 7 | Issue 8 | e1002174
IFN-c production, but not IL-2, (Figure 2 and Table 2, P= 0.002).
Due to the initial association of TLR6_G1083C with IL-2 in the
discovery dataset, we re-examined its association in the combined
dataset. The hypofunctional C allele was associated with higher
IFN-c and IL-2 production in the combined dataset (P= 0.021 and
0.008 for IFN-c and IL-2, respectively, Figure 2 and data not
Figure 1. Polymorphism TLR6_C745T is associated with BCG-induced whole blood cytokine production. Whole blood drawn 10 weeks
after BCG vaccination of newborns was re-stimulated with BCG for 7h ex vivo and plasma levels of IFN-c, IL-2, and IL-13 were measured. A general
linear model was used to examine whether polymorphism TLR6_C745T was associated with BCG-induced cytokine levels after subtraction of
unstimulated control values. IFN-c (A), IL-2 (B), and IL-13 (C) levels are shown with unstimulated control values subtracted for each genotype of
polymorphism TLR6_C745T. The number of individuals for each genotype is shown in parentheses. P values represent significant differences as
assessed using the general linear model. *P,0.05, **P,0.01, ***P#0.001.
doi:10.1371/journal.ppat.1002174.g001
Table 1. Association of TLR-pathway polymorphisms with cytokine responses following BCG vaccination in discovery cohort.a
AA Aa aa
SNP Cytokine N Mean SEM N Mean SEM N Mean SEM Pb
TIRAP_C539T IFN-c 209 916.00 93.98 16 761.50 217.18 2 988.32 1080.70 0.796
IL-2 209 566.10 50.43 16 385.50 64.55 2 330.64 349.60 0.297
IL-13 210 38.90 4.11 16 26.70 4.83 2 13.65 15.70 0.324
TIRAP_C558T IFN-c 186 916.90 96.19 37 846.40 233.53 3 199.47 261.90 0.502
IL-2 185 572.00 54.80 38 432.90 73.45 3 425.56 484.90 0.297
IL-13 186 39.50 4.52 38 29.50 5.22 3 14.43 24.80 0.294
TLR1_T1805G IFN-c 176 840.10 89.31 45 1256.80 268.30 3 246.64 275.10 0.200
IL-2 177 553.30 54.70 44 587.00 98.08 3 115.41 149.10 0.833
IL-13 177 36.40 3.96 45 46.70 11.25 3 12.82 16.40 0.521
TLR2_C597T IFN-c 83 765.20 128.65 110 981.30 133.13 32 262.99 1056.40 0.214
IL-2 82 484.40 57.50 111 617.80 81.07 32 94.36 522.30 0.506
IL-13 83 28.20 2.76 111 45.30 7.19 32 7.04 39.30 0.138
TLR4_A896G IFN-c 202 937.00 91.52 23 694.80 331.02 - - - 0.409
IL-2 202 564.30 50.57 23 479.40 125.05 - - - 0.586
IL-13 203 38.90 4.17 23 31.60 8.09 - - - 0.563
TLR4_C1196T IFN-c 215 896.90 86.22 11 892.20 678.34 - - - 0.991
IL-2 215 552.00 47.99 11 458.60 223.33 - - - 0.668
IL-13 216 37.50 3.93 11 39.70 16.37 - - - 0.905
TLR6_G1083C IFN-c 106 822.60 127.80 104 883.60 115.62 15 536.51 1744.70 0.070
IL-2 107 436.80 48.61 103 661.10 85.04 15 172.48 678.30 0.024
IL-13 107 32.90 3.44 104 44.00 7.34 15 11.39 35.60 0.320
TLR6_C745T IFN-c 191 815.00 85.72 32 1219.70 274.91 3 2199.76 3606.30 0.001
IL-2 192 532.20 51.30 31 614.40 113.04 3 626.08 1225.50 0.165
IL-13 192 37.20 4.34 32 41.80 7.14 3 23.09 46.70 0.625
aWhole blood from 10-week old infants vaccinated at birth with BCG was re-stimulated with BCG ex vivo for 7 hours and plasma levels of IFN-c, IL-2, and IL-13 were
measured in a discovery cohort sample set (n = 240).
bP value calculated from a general linear model that examined whether TLR polymorphisms were associated with BCG-induced cytokine levels after subtraction of
unstimulated control values.
doi:10.1371/journal.ppat.1002174.t001
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shown). In addition, TLR6_C745T was associated with IL-2
production (Figure 1, P = 0.031). There were no associations with
IL-13 production for any of these SNP. Each of these analyses
was also validated in population subgroups to ensure there was no
confounding from population admixture (Table S1). The other 4
polymorphisms were not associated with IFN-c, IL-2, or IL-13
levels (Table 2). We used a Bonferroni correction for multiple
comparisons in the secondary analysis due to the absence of a
validation sample set for this analysis. The association of
TLR1_T1805G with IFN-c remained significant after a Bonfer-
roni correction for multiple comparisons (P = 0.002615 (3
cytokine and 5 polymorphisms) = 0.03). The association of
TLR6_G1083C with IL-2 was not significant after correction.
Together, these results suggest that TLR1/6 hypofunctional
innate immune gene polymorphisms (TLR6_745T and
TLR1_1805G with statistical validation; TLR6_1083C without
validation) are associated with increased IFN-c or IL-2 levels after
BCG vaccination.
TLR1_A1188T, a TLR6/1/10 haplotype tagging
polymorphism, is associated with increased IFN-c and IL-
2 after BCG stimulation
TLR1 and TLR6 are located on chromosome 4 in a region
adjacent to TLR10 in a genomic region spanning 54 kb [40]
(Figure 3). To determine if any additional SNPs in this region
were associated with altered adaptive immune responses to BCG
stimulation, we genotyped 13 haplotype-tagging SNPs (Figure 3
and Table S3). TLR1 polymorphism A1188T (rs3923647) was
associated with increased IFN-c and IL-2 production in both
discovery and validation cohorts (P,0.001 and P= 0.002,
respectively for combined dataset; Figure 4A and B and Table
S3). The associations were also present in a subgroup analysis of
the SA Mixed Ancestry group (Table S1). There were no
statistical differences in IL-13 production (Figure 4C). Previous
studies suggest that the 1188T allele is associated with decreased
NF-kb signaling in HEK293 cells [41]. To determine if this SNP
resulted in regulated innate responses in primary cells, we
examined the production of TNF-a by peripheral blood
mononuclear cells in response to purified TLR ligands.
Although there were no statistically significant differences in
TNF-a production when comparing the 3 genotypes, there was a
trend towards lower cytokine response to the TLR1 ligand, tri-
acylated lipopeptide Pam3Cys (Figure 4D, n = 84, P = 0.098 vs
P = 0.227 for media control, 0.277 for Pam2Cys, and 0.863 for
LPS.).
Haplotype analysis of the four TLR polymorphisms
suggests independent associations with cytokine levels
To ascertain whether these cytokine associations were indepen-
dent, we measured the linkage disequilibrium (LD) among the loci
using pair-wise LD analysis in the South African mixed ancestry
group. R2 was less than 0.34 for all pair-wise calculations and less
than 0.1 for the majority, suggesting a low level of linkage
disequilibrium between these polymorphisms (Figure 2). We next
examined whether pairwise diplotype combinations of the
polymorphisms were associated with further differences in IFN-c
and/or IL-2 levels. Due to several low polymorphism frequencies,
only SNP G1083C could be assessed in combination with the
others. We found no diplotype combinations that resulted in
additive effects (data not shown). Taken together, these results
suggest that each of the four SNPs individually contributes to the
association with BCG-induced immune responses and that
combination of these polymorphisms does not further increase
the magnitude of the response.
Table 2. Secondary analysis of association of TLR polymorphisms with BCG-induced cytokines in combined dataset.a
MAFb AA Aa aa
SNP Cytokine N Mean SEM N Mean SEM N Mean SEM Pc
TIRAP_C539T IFN-c 0.041 414 878.80 64.54 31 813.90 158.29 3 971.20 581.05 0.871
IL-2 412 539.50 32.53 31 512.80 82.89 3 499.80 242.89 0.809
IL-13 415 36.50 2.45 31 67.50 37.97 3 21.10 9.53 0.086
TIRAP_C558T IFN-c 0.078 377 897.40 66.83 61 787.10 161.01 4 216.70 148.10 0.307
IL-2 374 550.50 34.61 62 463.60 64.83 4 390.30 315.45 0.281
IL-13 377 37.10 2.61 62 49.60 19.34 4 19.90 11.30 0.382
TLR1_T1805G IFN-c 0.104 356 783.90 57.22 85 1256.70 202.85 4 1298.00 1037.70 0.002
IL-2 355 513.40 33.65 84 645.70 76.22 4 519.40 379.15 0.128
IL-13 357 38.40 4.07 85 41.40 6.32 4 25.60 12.95 0.866
TLR4_A896G IFN-c 0.043 407 878.20 62.39 38 745.90 222.60 0 - - 0.539
IL-2 405 547.00 32.77 38 442.30 80.49 0 - - 0.341
IL-13 408 39.00 3.73 38 35.20 7.61 0 - - 0.759
TLR4_C1196T IFN-c 0.023 424 876.70 61.53 20 806.20 371.37 0 - - 0.811
IL-2 422 540.60 31.71 20 430.90 124.12 0 - - 0.459
IL-13 425 38.70 3.62 20 37.90 9.21 0 - - 0.965
aWhole blood from 10-week old infants vaccinated at birth with BCG was re-stimulated with BCG ex vivo for 7 hours and plasma levels of IFN-c, IL-2, and IL-13 were
measured in a combined sample set (n = 480).
bAbbreviations: MAF, minor allele frequency.
cP value calculated from a general linear model that examined whether TLR polymorphisms were associated with BCG-induced cytokine levels after subtraction of
unstimulated control values.
doi:10.1371/journal.ppat.1002174.t002
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Two TLR polymorphisms (TLR6_C745T and
TLR1_T1805G) are associated with increased expression
of T cell cytotoxicity molecules
To examine T cell function in greater detail in an exploratory
analysis of the 4 polymorphisms (TLR6_C745T, TLR6_G1083C,
TLR1_T1805G, TLR1_A1188T) in a subset of individuals
(n = 65), we measured the expression of cytotoxic mediators
granulysin, granzyme B, and perforin as well as T cell proliferation
(Figure 5 and Figure S1). Due to the smaller sample set, some of
the analyses had reduced power from low minor allele frequencies.
TLR6 polymorphism C745T was associated with CD4-specific
expression of granulysin (p,0.005) and granzyme B (p,0.05),
while both TLR6_C745T and TLR1_T1805G were associated
with perforin expression (p,0.02). In addition TLR6_C745T was
associated with increased granzyme B, but not granulysin or
perforin, in CD8+ T-cells. TLR1_T1805G was associated with
increased perforin in CD8+ T-cells. In contrast, neither polymor-
phism affected T cell proliferation (Figure S1). When adjusted for
multiple comparisons with a Bonferroni correction, these associ-
ations were not statistically significant. TLR1_A1188T and
TLR6_G1083C were not associated with altered T cell function
as measured by production of cytotoxic effector molecules or
proliferation (Figure 5 and Figure S1). Together, these results
suggest that some of the polymorphisms associated with plasma
IFN-c or IL-2 were also associated with expression of BCG-
induced CD4 and CD8 T-cell cytotoxic markers.
TLR1/6 deficiency is associated with decreased
lipopeptide-induced IL-10 secretion
We next examined possible mechanisms underlying the
association of hypofunctional TLR1 and TLR6 polymorphisms
with increased levels of BCG-induced IFN-c from T-cells. We
hypothesized that TLR1/6 polymorphisms are associated with
altered T-cell responses through regulation of IL-10 and IL-12
secretion from monocytes. After stimulating PBMCs or monocytes
with TLR ligands (LPS, PAM2 (PAM2CSK4), PAM3
(PAM3CSK4), and TB whole cell lysate), we were unable to detect
IL-12p70 in cellular supernatants (Figure S2). In contrast, IL-10
was readily detectable, although at levels substantially lower than
IL-6. To determine whether TLR1 and TLR6 polymorphisms
were associated with IL-10 secretion, we stimulated PBMCs from
47 individuals with known TLR1_T1805G and TLR6_C745T
genotypes. We stratified individuals into those who had hypofunc-
tional genotypes for both TLR1 and TLR6 (TLR1/6_low
represented by TLR1_1805GG and TLR6_745TT/CT) versus
those with wild-type functional genotypes for both genes (TLR1/
6_high represented by TLR1_1805GT/TT and TLR6_745CC).
TLR1/6_low individuals had decreased levels of PAM2 and
PAM3-induced IL-6 in comparison to TLR1/6_high individuals
(Figure 6A). The TLR1/6_low individuals had lower PAM3-
induced IL-10 levels in comparison to TLR1/6_high (Figure 6B).
PAM2-stimulated IL-10 levels did not differ, although the level of
induction was minimal. Interestingly, the TB-induced IL-6, but
not IL-10, levels were lower in the TLR1/6_low group when
compared to TLR1/6_high (Figure 6A and B). As a control, LPS-
induced levels did not differ for IL-6 or IL-10. IL-12p70 was not
detectable in any of the samples. We next examined the
association of the individual polymorphisms with cytokine levels.
Due to linkage disequilibrium between the 2 polymorphisms, the
individual SNP analysis does not completely distinguish the
separate effects of each polymorphism (R2= 0.26; D’ = 0.81),
Similar to our previous studies, we found that genotypes
TLR1_1805GG and TLR6_745CT/TT were associated with
lower IL-6 levels in comparison to genotypes TLR1_T1805GT/
TT and TLR6_745CC (Figure 6C and E) [27,33]. We also found
that genotype TLR1_1805GG was associated with lower IL-10
production in comparison to TLR1_1805GT/TT (Figure 6D). In
Figure 2. Polymorphisms TLR6_G1083C and TLR1_T1805G are associated with BCG-induced whole blood cytokine production.
Whole blood drawn 10 weeks after BCG vaccination of infants was re-stimulated with BCG for 7h ex vivo and plasma levels of IFN-c, IL-2, and IL-13
were measured. A general linear model was used to examine whether TLR polymorphisms were associated with BCG-induced cytokine levels after
subtraction of unstimulated control values. IFN-c, IL-2, and IL-13 levels are shown with unstimulated control values subtracted for each genotype of
polymorphism TLR1-T1805G (A–C) and TLR6_G1083C (D–F). The number of individuals for each genotype is shown in parentheses. P values represent
significant differences as assessed using the general linear model. *P,0.05, **P,0.01.
doi:10.1371/journal.ppat.1002174.g002
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contrast, TLR6_C745T genotypes were not associated with IL-10
levels (Figure 6F). As a control, these 2 polymorphisms were not
associated with LPS-induced IL-6 secretion. Together, these data
suggest that genetic regulation of monocyte production of IL-10 by
TLR1/6 genetic variants (with the primary association probably
due to TLR1_T1805G) provides a possible mechanism for the
alteration of IFN-c production by T-cells in BCG-vaccines.
Discussion
The main finding of this study is that 4 well-defined
hyporesponsive TLR polymorphisms are associated with increased
ex vivo BCG-induced whole blood IFN-c or IL-2 responses 10
weeks after in vivo BCG vaccination of newborns. To our
knowledge, this is the first description of polymorphisms in innate
pathway genes that affect the adaptive response to in vivo
vaccination against a bacterial pathogen in humans. Various in
utero and postpartum factors are likely to influence the immune
response to BCG vaccination in newborns, including nutritional
status, immunosuppression, antigen sensitization, and exposure to
environmental mycobacteria. This study suggests that host genetic
factors are associated with BCG vaccine responsiveness. Our
findings are unlikely to be confounded by other factors as all
infants were HIV-negative with similar nutritional status with
exclusion of infants who had acute or chronic illnesses. Although
evidence indicates that environmental bacteria modulate the
immune response to BCG vaccination [4,42], this variable is
unlikely to confound our results since the infants received BCG at
birth and would have minimal additional exposure during the 10
week follow-up. Previous studies indicate that BCG vaccination
induces a potent Th1 response to mycobacterial antigens in
newborns [43] with a wide range of IFN-c levels [18]. Our data
suggest that these previous observations may be partially
attributable to variation in TLR1 or TLR6 and that host genetics
are an important variable influencing the immune response to
BCG vaccination.
One consistent and important pattern of association was that
the hyporesponsive TLR1 or TLR6 allele was associated with
increased IFN-c or IL-2 levels after BCG vaccination. The
molecular and cellular mechanisms by which these polymorphisms
are having opposing effects on cytokine production are only
partially understood. At the molecular level, each of the SNPs that
had correlations with BCG responses in this study have previously
been associated with decreased responsiveness to stimulation with
purified TLR ligands in innate immune signaling assays (primary
monocytes or transfected cell signaling assays). For example, we
and others have shown that TLR1_T1805G regulates signaling in
response to lipopeptide stimulation and essentially defines TLR1
deficiency in humans [26,28,34,38,44]. Studies of TLR1_1805GG
individuals offer study design advantages similar to using Tlr1-/-
mice, while avoiding the limitations of the mouse model. The
second TLR1 polymorphism that was found to be associated with
Figure 3. Haplotype tagging SNPs and pair-wise linkage disequilibrium analysis of TLR1-6-10 gene region. A. The arrangement of TLR1
TLR6 and TLR10 on chromosome 4 and the position of the haploytype-tagging SNPs are shown. B. Linkage disequilibrium analyses between the four
TLR SNPs with functional associations in this study are expressed as D’ and R2 for pair-wise comparisons. The minor allele frequencies (MAF) are listed
in the top row of boxes and highlighted in bold.
doi:10.1371/journal.ppat.1002174.g003
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increased production of Th1 cytokines was A1188T, a non-
synonymous SNP that results in an amino acid change from
histidine to leucine (H305L). This SNP has not been as well
characterized, but was shown in one study to be associated with
partially reduced signaling after stimulation with synthetic
lipopeptides in transfected cells [41]. We recently found that
TLR6_C745T and TLR6_G1083C were associated with de-
creased IL-6 in response to lipopeptide stimulation in a whole
blood cytokine assay. In addition, the TLR6_745T variant
mediated less NF-kB signaling in a transfected HEK cells in
response to stimulation with di-acylated lipopeptide or Mtb cell
lysate. These findings correspond with our TLR1 results, where
hyporesponsive variants in innate assays are associated with
hyperresponsive Th1 T-cell cytokine production after BCG
vaccination. The functional effect of the synonymous SNP
G1083C is not currently known. This variant may be in linkage
disequilibrium with a regulatory or coding region non-synony-
mous polymorphism, or it could directly regulate TLR6 mRNA
expression.
The cellular mechanism underlying the association of TLR1
and TLR6-deficiency with increased Th1 T cell cytokine
responses is also not known, but is likely secondary to effects on
antigen presenting cells (APCs) such as monocytes, macrophages,
and dendritic cells and their interactions with T cells. Alternative
mechanisms include stimulation of TLRs on other cells such as
neutrophils, T cells, or stromal cells at the vaccination site.
Modulation of T-cell function by APCs could occur through
several mechanisms including cytokine effects, genetic regulation
of signaling pathways, and the activation of distinct immune
responses by different innate immune receptors. Monocyte and
dendritic cell-derived IL-12 induces and maintains the polariza-
tion of IFN-c producing TH1 T-cells [45]. In contrast, IL-10 is an
anti-inflammatory cytokine with pleiotropic effects including
inhibition of IL-12 secretion and TH1 polarization [46,47]. The
ratio of IL-10 and IL-12 produced by APCs could influence the
induction and/or maintenance of a TH1 polarized response. We
found that PBMCs and monocytes secreted IL-10, but not IL-
12p70 after stimulation with a panel of TLR ligands. In addition,
TLR1/6 deficiency was associated with lower IL-10 levels. The
genetic regulation of IL-10 levels in the absence of IL-12 provides
a plausible mechanism whereby APC TLR1/6 deficiency could be
associated with an increased TH1 T-cell response. Our ex vivo
Figure 4. TLR1 polymorphism A1188T is associated with increased Th1 cytokine production in response to BCG stimulation. A-C. As
in Figure 1, whole blood drawn 10 weeks after BCG at birth was re-stimulated with BCG for 7h ex vivo. Plasma IFN-c (A), IL-2 (B), and IL-13 (C) levels are
shown for individuals with TLR1 polymorphism A1188T (rs3923647) with the number of individuals for each genotype shown in parentheses. D.
PBMCs from individuals vaccinated with BCG were stimulated with media or TLR ligands (LPS (100 ng/mL), PAM2CSK4 (250 ng/mL), PAM3CSK4
(250 ng/mL)) for 24 hours. TNF-a production was quantified by ELISA. **P,0.01, ***P#0.001.
doi:10.1371/journal.ppat.1002174.g004
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experimental conditions model a limited portion of the in vivo
vaccination environment which includes multiple sites (e.g.
vaccination site, lymph node, spleen, peripheral blood), various
inflammatory milieus (with mixture of pro and anti-inflammatory
cytokines from multiple cell types), and complex kinetics.
Nevertheless, our ex vivo data demonstrates how TLR1/6
deficiency could promote TH1 T-cell polarization under some
conditions.
In addition to genetic regulation of cytokine responses, the
immune response is influenced by the specific innate immune
receptors that are stimulated. Murine studies indicate that TLRs
regulate cytokine production and maturation of DCs with
subsequent modulation of T cell responses [48][49][50]. The
degree and type of response (Th1 vs. Th2 vs. Th17) is modulated
by which innate immune receptor is activated, including
stimulation of Th1 responses by TLR4,7,8, and 9, Th2 responses
by TLR2, and Th17 responses by NOD2. Our data is consistent
with the murine studies which show that lack of TLR2 stimulation
(via its heterodimeric partner TLR1 or TLR6) may promote an
enhanced Th1 response. Mtb stimulates cells through several
innate immune receptors, including TLR1,2,6,9, NOD2, DC-
SIGN, CD43, Mincle, Marco and possibly TLR4, 8 and Dectin-1
[10,51,52,53,54,55,56]. With this diverse repertoire of receptors,
several distinct T cell phenotypes may be promoted. Future
identification of human deficiencies in other receptors will
illuminate the mechanisms of innate immune modulation of
T-cell responses and holds potential for rational selection of
adjuvants.
There are several potential limitations of our study. Although
the ex vivo BCG stimulation whole blood cytokine assay offers
advantages of convenience and reproducibility for use in a large
scale field trial, the cellular source of IFN-c or IL-2 production
is not identified with this method. In addition, the response is
not antigen-specific due to the complex composition of BCG
with both T cell antigens and ligands of innate immune
receptors. We chose to examine IFN-c, IL-2, and IL-13 since
they are predominantly produced by T, NK, or NKT cells
rather than monocytes, dendritic cells, neutrophils, or B cells.
Previous studies by our group and others suggest that IFN-c is
almost exclusively made by T cells rather than NK or NKT cells
in this assay [57,58]. While this study focused on TLR-mediated
immune responses to BCG vaccination, several addition PRRs
that recognize mycobacterial antigens were not investigated
including NOD2, DC-SIGN, Mincle (CLEC4E), dectin-1, and
the mannose receptor [10]. This study also has numerous
strengths including sample size, the presence of distinct
discovery and validation sample sets, a standardized in vivo
vaccination protocol given at a uniform age, and a consistent
follow-up time point for assessing immune responses. To our
knowledge, the combination of these study design features is
novel and illuminates a unique role for TLR deficiencies in
BCG vaccine responsiveness.
Figure 5. Two TLR polymorphisms are associated with increased expression of cytotoxic molecules after ex vivo BCG stimulation.
Whole blood drawn 10 weeks after BCG at birth was re-stimulated with BCG ex vivo for 3 days. Granulysin, granzyme B and perforin production were
measured by intracellular cytokine staining in (A) CD4-positive and (B) CD8-positive T cells. A general linear model was used to examine whether 4
TLR polymorphisms (TLR1_T1805G, TLR1_A1188T, TLR6_G1083C, and TLR6_C745T) were associated with BCG-induced cytotoxicity markers after
subtraction of unstimulated control values. *P,0.05, **P,0.01.
doi:10.1371/journal.ppat.1002174.g005
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There are several potential impacts these findings may have on
the development of novel diagnostics and prevention efforts for
TB. For example, Mtb-specific T cell responses (PPD skin testing
and more recently Interferon-Gamma Release Assays) have been
used for over 100 years for diagnosing latent and active TB. Our
observations are consistent with those of Cobat et al and support
the concept that the genetic background of patients influences the
results of immunodiagnostic tests and that alternative assays may
need to be developed that are not dependent on host genetic
variation [12,13]. As an extreme example, the G allele of
polymorphism TLR1_T1805G is rare in Asia and Africa, yet
the most common allele in Europe and North America [27,44].
Moreover, these results could potentially affect how we test
vaccine efficacy in clinical trials. Because IFN-c responses are
often used to measure immunity to new vaccines in clinical trials,
genetic differences may confound measurements of efficacy in such
trials. Genotypes may need to be considered when analyzing
efficacy data and our results could also potentially identify risks for
vaccine failure.
Children with Mendelian disorders associated with an inability
to produce or respond to IFN-c (i.e. mutations in IL-12R, IL-
12p40, and IFNcR1/R2) are highly susceptible to disseminated
mycobacterial infection [59]. Our data describes a new genetic
mechanism that could modulate IFN-c levels in response to
Mycobacteria. Although we do not currently know if these
polymorphisms are associated with altered susceptibility to
pediatric TB in our population, ongoing studies will address this
question. Furthermore, recent work from our group and others
suggests that TLR1-deficiency is clinically relevant with an
association in several studies with susceptibility to leprosy and
leprosy reversal reaction [26,28,44]. Further investigation is also
warranted to address the kinetics of immune responses in BCG
vaccinated infants as in this study we were limited by only one
time-point and it is possible that variation is not sustained or that
immunity may wane.
In summary, we examined BCG-induced cytokine responses
in vaccinated infants and found that IFN-c and IL-2 responses
are dependent upon the genetic background of study partici-
pants. Taken together, these findings suggest that defects in
innate pathway genes modulate adaptive responses to patho-
gens by altering the production of BCG-induced cytokines by T
cells.
Methods
Ethics statement
All protocols for this study were approved by the Research
Ethics Committee of the University of Cape Town and the
Institutional Review Boards at the University of Washington and
University of Medicine and Dentistry of New Jersey. Ethical
guidelines of the US Department of Health and Human Services
and the South African Medical Research Council were adhered
to, including written informed consent from parents of study
participants.
Ligands and antigens
Ultrapure lipopolysacharide (LPS, TLR4 ligand, used in whole
blood assays at 10 ng/mL, concentration in other assays
mentioned below) isolated from Salmonella minnesota R595 was
obtained from List Biological Labs, Inc. (Campbell, CA, USA).
The lipopeptides PAM2 (PAM2CSKKKK, S-[2,3-bis(palmitoy-
loxy)-propyl]-(R)-cysteinyl-(lysyl)3-lysine, TLR2/6 ligand), and
Figure 6. TLR1/6 polymorphisms are associated with decreased lipopeptide-induced IL-6 and IL-10 production in PBMCs. PBMCs
from individuals with polymorphisms in TLR6_C745T and TLR1_T1805G were stimulated for 20 hours with TLR ligands LPS (10 ng/mL), PAM2CSK4
(250 ng/mL), or PAM3CSK4 (250 ng/mL). Supernatant IL-6 and IL-10 levels were quantified by ELISA. TLR1 and TLR6 genotypes are designated based
on functionality as: TLR1_low (genotype TLR1_1805GG, n = 22), TLR1_high (1805GT/TT, n = 25), TLR6_low (TLR6_745CT/TT, n = 24), or TLR6_high
(745CC, n = 23). TLR1/6 diplotypes are designated as TLR1/6_low (TLR1_1805GG and TLR6_745CT/TT, n = 18) or TLR1/6_high (TLR1_1805GT/TT and
TLR6_745CC, n= 18). Panels: For IL-6, TLR1/6_low vs high diplotypes (A), TLR6_low versus high genotypes for (B), and TLR1_low versus high
genotypes for IL-6 (C). For IL-10, TLR1/6_low vs high diplotypes for media, PAM2, and PAM3 (D) or LPS (E); TLR6_low versus high genotypes for media,
PAM2, and PAM3 (F) or LPS (G); TLR1_low versus high genotypes for media, PAM2, and PAM3 (H) or LPS (I). Diplotypes and genotypes with normal
signaling (high) designated with a box with dots while deficient signaling (low) designated with clear box. P values represent significant differences
as assessed by a Mann-Whitney U-test for comparison of low versus high groups. *P,0.05, **P,0.01, ***P#0.001.
doi:10.1371/journal.ppat.1002174.g006
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PAM3 (Pam3CSKKKK, N-palmitoyl-S-[2,3-bis- (palmitoyloxy)-
propyl]-(R)-cysteinyl-(lysyl)3-lysine, TLR2/1 ligand) were synthetic
lipopeptides obtained from EMC Microcollections (Tuebingen,
Germany). Lysate from Mtb strain H37Rv (25 mg/mL) was
obtained from J. Belisle (Colorado State University, Fort Collins,
CO, USA; NIAID reagent contract). Lyophilized live Bacille
Calmette-Guerin (BCG, 20 x 106 CFU/mL) was obtained from
Statens Serum Institute (Copenhagen, Denmark).
Study population
Healthy infants, routinely vaccinated with intradermal BCG
(Danish strain 1331; Statens Serum Institut, Copenhagen, Den-
mark) at birth, were enrolled from the South African Tuberculosis
Vaccine Initiative (SATVI) field site in the Worcestor region, a
rural area outside Cape Town, South Africa. HIV prevalence is
very low in this region, while TB incidence is among the highest in
the world [58]. Infants were excluded if known to be HIV-infected
(upon rapid testing at enrollment site) or born to HIV-infected
mothers. Infants with suspected or confirmed TB and those in
contact with adults with pulmonary TB were also excluded as were
infants with any other acute or chronic diseases or clinically
apparent anemia at the time of enrollment. Suspected TB cases
were referred to the SATVI clinical center where they were
evaluated for diagnosis. Other exclusion criteria included infants
who did not receive the BCG vaccination within 48 hours of birth,
significant perinatal complications in the infant, and low birth
weight infants (,2.5 kg). The overall ethnic distribution in this
region is approximately 80% South African mixed ethnicity
(genetically influenced by Malaysian, Indonesian, European
Caucasoid and black African ethnic groups), 20% black African,
and less than 1% Caucasian.
Blood collection and stimulation and cryopreservation
At 10 weeks of age, heparinized blood was collected from BCG-
vaccinated infants and 1mL was incubated ex vivo with
1.26106 CFU of BCG (Danish strain 1331). None of the infants
in this study had active tuberculosis at the time of their 10 week
blood draw or during 2 years of follow-up observation. Cytokine
production was assessed in plasma harvested after a 7 hour
incubation of whole blood with or without BCG. IFN-c, IL-2 and
IL-13 levels were measured by multiplex bead array technology
according to manufacturer’s instructions (Bio-Rad, Hercules, CA,
USA) and read on a luminometer (Luminex, Austin, TX, USA).
The range of detection for all cytokines was 2-32,000 pg/mL.
Basal cytokine levels measured in plasma harvested from
unstimulated blood were subtracted from values obtained from
BCG-stimulated blood. Cells were also harvested at 72 hours and
cryopreserved for T cell cytotoxicity and proliferation assays.
Cytokine production in PBMCs after stimulation with
purified TLR ligands
Cytokine assays were performed on PBMCs from infants in the
South Africa vaccine cohort as well as adult healthy volunteers in
Seattle. Study participants in Seattle were healthy adults with no
known history of unusual susceptibility to infections. Peripheral
blood mononuclear cells (PBMCs) were isolated from whole blood
separated by centrifugation on a Ficoll-Hypaque gradient, plated
at a density of 16105 cells per well in 96-well plates in RPMI
(Invitrogen, Carlsbad, CA) +10% FBS (Invitrogen, Carlsbad, CA),
and incubated overnight. For cells from South Africa (n = 87), cells
were stimulated for 24 hours with 250 ng/mL of PAM2CysK4
and PAM3CysK3or ultrapure LPS at 100 ng/ml. For cells from
Seattle adult donors (n = 47), PBMCs were stimulated for 24 hours
immediately after isolation with media, 250 ng/mL PAM2CSK4,
250 ng/mL PAM3CSK4 10 ng/ml LPS or 25 ucg/mL Mycobac-
terium tuberculosis (MTB) whole cell lysate. Supernatants were
harvested and cytokines were measured using a sandwich ELISA
(R&D Systems, Minneapolis, MN).
T cell functional assays
Cryopreserved cells were thawed and incubated with 1 mL 1X
Perm/Wash solution (BD Biosciences) for 10 minutes at room
temperature to permeabilize cells. Cells were then washed and
stained for 1 hr before samples were analyzed on a BD LSRII flow
cytometer (BD Biosciences). For proliferation assays, cells were
stained with CD4-PerCP (SK3), CD8-PerCPCy5.5 (SK1) and PE
(B56) from BD Biosciences and CD3-QDot 605 (UCHT1)
(Invitrogen). For cytotoxicity assays, cells were stained with
CD3-Pacific Blue, CD4-Qdot 655, Ki67-PE, Perforin-APC,
Granzyme B-Alexa Fluor 700 and Granulysin-Alexa Fluor 488,
CD27-Qdot 655, CD28-PerCP-Cy5.5.
Genomic techniques
PBMC isolated from study participants in South Africa were
sent to Seattle, WA lab, where genomic DNA was obtained by
purification using the QIAamp DNA blood kit (Qiagen) according
to manufacturer’s instructions. Genotyping of DNA was per-
formed using a chip-based MALDI-TOF MassARRAY technique
(Sequenom) as previously described. SpectroDESIGNER software
was used to determine probes to be used for multiplex SNP assays;
5 ng of DNA was amplified in a 384-well plate following
Sequenom’s specifications. Shrimp alkaline phosphatase was
added after PCR to prevent further incorporation of unused
dNTPs that might interfere with the primer extension step. Next,
allelic discrimination reactions were performed by adding a
mixture of dNTPs and dideoxy NTPs to each well. MassEX-
TEND clean resin was added to the mixture to remove extraneous
salts that could interfere with the MALDI-TOF analysis.
Genotypes were determined by spotting 15 nL of each reaction
onto a 386 SpectroCHIP (Sequenom), which was subsequently
read by the MALDI-TOF mass spectrometer. For our primary
analysis, we genotyped 9 well-characterized TLR-pathway SNPs
which are associated with altered TLR gene function and/or
susceptibility to different infections. The polymorphisms include
TLR1_G1805T (amino acid (AA) change S602I, rs5743618),
TLR2_T597C (AA N199N, rs3804099), TLR2_G2258A (AA
R753Q, rs5743708), TLR4_A896G (AA D299G, rs4986790),
TLR4_C1196T (AA T399I, rs4986791), TLR6_C745T (AA
P249S, rs5743810), TLR6_G1083C (AA T361T, rs3821895)
TIRAP_C539T (AAS180L, rs8177374), and TIRAP_C558T
(AA A186A, rs7932766). Polymorphism TLR2_G2258A had only
one heterozygote and was not further analyzed due to lack of
variation.
Statistical analysis
We examined whether polymorphisms were associated with
cytokine levels with an allelic trend test using a general linear
model (GLM) and results were expressed as mean +/2 standard
error of the mean. In the allelic trend test (also called a log-additive
model) common homozygous genotypes (00) were assigned a value
of 0, heterozygotes (01) a value of 1, and minor homozygous
genotypes (11) a value of 2. The primary analysis examined
whether 9 functionally characterized polymorphisms were associ-
ated with cytokine levels in a discovery sample set (n = 240). To
avoid a Type I error from multiple comparisons, we analyzed
initial findings in a validation sample set of the same size. Subjects
were randomly assigned to discovery and validation sample sets
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using SPSS statistical software (SPSS for Windows, Rel. 15.0.1.
2006. Chicago: SPSS Inc.) As a secondary analysis, we also
examined the combined dataset (n = 480) to identify associations
involving low frequency polymorphisms. Two-sided testing was
used for all comparisons to evaluate statistical significance,
considering a P-value of #0.05 as significant. All analyses were
performed using Stata (Intercooled Version 10.1, Statacorp LP;
College Station, TX, USA). Cytokine data from TLR-stimulated
PBMCs was analyzed with a Mann-Whitney U test due to the
smaller sample size.
All SNPs analyzed were in Hardy Weinberg equilibrium with a
P value cutoff of ,0.001 in the South African Mixed Ancestry
group indicating that there were no genotyping errors or major
effects of population heterogeneity. To verify that our significant
findings were not due to population admixture, we also performed
South African Mixed Ancestry subgroup analyses. Stata program
PWLD was used to calculate R2 and D’ as measurements of
linkage disequilibrium between the polymorphisms. To identify
haplotype tagging SNPs, we examined data from the YRI
(Yorubans in Nigeria) and CEU (Utah residents with European
ancestry) populations from the International HapMap Project
(http://www.hapmap.org) and other public databases with the
Genome Variation Server (http://www.ncbi.nlm.nih.gov/SNP/
and www.innateimmunity.net). We searched a region on chromo-
some 4, 50 kilobases upstream and downstream of genes for
TLR1, TLR6, TLR10, as well as TLR2 for tagged SNPs using an
R2 cutoff of 0.8 for linkage disequilibrium and a minor allele
frequency cut-off of 5%.
Supporting Information
Figure S1 TLR polymorphisms do not affect prolifera-
tion of T cells after ex vivo BCG stimulation. Whole blood
drawn 10 weeks after BCG at birth was restimulated with BCG ex
vivo for 72 hours. Cell proliferation was measured in CD4-positive
(A) and CD8-positive (B) T cells after ex vivo BCG re-stimulation of
whole blood from infants vaccinated with BCG at birth. A general
linear model was used to examine whether TLR polymorphisms
were associated with proliferation after subtraction of unstimulated
control values.
(TIF)
Figure S2 TLR ligands induce IL-10, but not IL-12p70,
in monocytes and PBMCs. PBMCs and monocytes were
isolated from 6 donors and stimulated for 20 hours with media,
LPS (10 ng/mL), PAM2CSK4 (250 ng/mL), or PAM3CSK4
(250 ng/mL). Supernatant IL-10 (A) and IL-12p70 (B) levels were
quantified by ELISA. IL-10, but not IL-12p70, was detectable in
both PBMCs and monocytes.
(TIF)
Table S1 Association of TLR-pathway polymorphisms
with cytokine responses following bcg vaccination in
discovery cohort. Whole blood from 10-week old infants
vaccinated at birth with BCG was re-stimulated with BCG ex vivo
for 7 hours and plasma levels of IFN-c, IL-2, and IL-13 were
measured in a discovery cohort sample set (n = 240). P values were
calculated from a general linear model that examined whether
TLR polymorphisms were associated with BCG- induced cytokine
levels after subtraction of unstimulated control values.
(DOCX)
Table S2 Analysis of population admixture with 21
ancestry informative markers. Population admixture was
analysed using 21 ancestry informative markers. At each locus, x2
represents Pearson’s x2 value for comparison of allele frequencies
in groups of low (less than median) and high (greater than median)
cytokine responses in the South African Mixed Ancestry Group. A
global p value was calculated for the mean x2 value for the 21
SNPs for each cytokine. For IFN-c, IL-2, and IL-13, the global p
values were 0.40, 0.38, and 0.39, respectively. Chrom, chromo-
somal location of SNP; Low, group of individuals with cytokine
value below median; High, group of individuals with cytokine
value above the median; HWE, Hardy-Weinberg Equilibrium;
MAF, minor allele frequency.
(DOCX)
Table S3 Association of polymorphisms in TLR1-6-10
locus with BCG-induced cytokine response. Whole blood
from 10-week old infants vaccinated at birth with BCG was re-
stimulated with BCG ex vivo for 7 hours and plasma levels of IFN-
c, IL-2, and IL-13 were measured in a discovery cohort sample set
(n = 240). P values were calculated from a general linear model
that examined whether TLR polymorphisms were associated with
BCG-induced cytokine levels after subtraction of unstimulated
control values.
(DOCX)
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